Genmab
Research Genmab (GMAB.CO) on Bullrun: market cap DKK 148.34B, P/E 29.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGMAB.CO
- ExchangeXCSE
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 148.34B
- P/E29.3
- Financial periodQ2 2026
- RevenueUSD 1.16B
- Net incomeUSD 303.00M
- Free cash flowUSD 48.00M
- Gross margin92.7%
Valuation Snapshot
latest market cap is DKK 148.34B; P/E is 29.3.
Peer valuation comparison
Latest P/E is 29.32x versus a Healthcare sector median of 21.69x (35.1% above).
Latest P/E is 29.32x versus a Denmark median of 17.52x (67.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.72B | USD 963.00M | USD 1.15B | 93.6% | 15.37 | USD 1.52B | USD 5.21B | USD 5.68B |
| FY2024 | USD 3.12B | USD 1.13B | USD 1.10B | 95.4% | 17.53 | USD 1.38B | USD 0 | USD 5.14B |
| FY2023 | USD 2.39B | USD 631.00M | USD 1.02B | 98.6% | 9.58 | USD 2.20B | USD 0 | USD 4.69B |
| FY2022 | USD 2.07B | USD 779.31M | USD 513.87M | 100.0% | 11.81 | USD 1.42B | n/a | USD 3.92B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | DKK 148.34B | 29.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genmab's market cap?
Genmab's market capitalization is DKK 148.34B.
What is Genmab's P/E ratio?
Genmab's price-to-earnings (P/E) ratio is 29.3.
What does Genmab do?
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.